Navigation Links
A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
Date:2/26/2009

Pfizer's Axitinib Earns Decision Resources' Gold-Standard for Renal Cell Carcinoma in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a first-line therapy for metastatic renal cell carcinoma that can increase overall survival in comparison with Pfizer's Sutent would earn a 50 percent patient share in the United States and a 35 percent patient share in Europe, according to surveyed U.S. and European oncologists.

The new report entitled Renal Cell Carcinoma (Metastatic): Axitinib's Improvements in Overall Survival will Differentiate it from Current and Emerging Therapies finds that a therapy's effect on overall survival is the attribute that most influences surveyed oncologists' prescribing decisions in metastatic renal cell carcinoma. Clinical data and the opinions of interviewed thought leaders indicate that Pfizer's axitinib has advantages over Sutent in this attribute. Sutent, the market sales leading agent, was Decision Resources' proprietary clinical gold standard in 2008 for metastatic renal cell carcinoma.

Based on available data and expert opinion, axitinib will earn gold-standard status for metastatic renal cell carcinoma in 2012 through 2017, following its approval for the indication in 2011. Interviewed experts anticipate that axitinib, which has competitive advantages and has shown impressive Phase II survival data in the second-line setting, will be more effective than Sutent.

"In the second-line setting, axitinib has shown an increase in median overall survival in clinical trials," said Decision Resources Analyst Laila Siddique. "This median overall survival is slightly longer than the overall survival observed with Sutent in the first-line setting. Axitinib's data are particularly impressive becaus
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
2. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
3. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
4. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
5. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
6. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
7. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
8. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
9. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
10. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
11. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... VIEW, Calif. , Aug. 31, 2015 /PRNewswire/ ... for flow cytometry is experiencing a rise in ... the demand in underdeveloped nations to quantitate CD4 ... Logo - http://photos.prnewswire.com/prnh/20150831/262206LOGO ... Analysis of the Global Flow Cytometry Market ( ...
(Date:8/31/2015)... HARRISBURG, Pa. , Aug. 31, 2015 ... been reversed statewide since Pennsylvania ... the life-saving drug kits, naloxone. Heroin and ... in Pennsylvania , killing more individuals ... 2013, approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... , Aug. 31, 2015  The departments of ... event today at Gaudenzia Concept 90 to raise awareness ... overdose crisis in Pennsylvania and ... and focus on recovery through the Building Bridges ... Pennsylvanians are dying every day to a disease that ...
Breaking Medicine Technology:Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2
... Phase 1 Colorectal and Prostate Cancer,Trials To Be ... FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, ... announced that data from a Phase 2 trial,of ... small cell lung cancer (SCLC) will be presented ...
... Urine Flow, With,Long Lasting Effect in Phase 2 ... Spectrum,Pharmaceuticals, Inc., today announced Phase 2 safety and ... the treatment,of benign prostatic hypertrophy (BPH), at the ... Convention Center in,Anaheim, California on Tuesday, May 22, ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 2Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 3Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 4Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 2Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 3Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 4Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 5
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... announced the release of version 5.2 of the FirstSpirit Content Management System with ... initiative. With the new version of FirstSpirit, companies will be well on their ...
(Date:9/1/2015)... ... September 01, 2015 , ... Two of Washington D.C.’s most respected ... food and dining. , Recently named “the next big thing” in the culinary ... for telling the whole story behind food and reclaiming culinary traditions on the brink ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... the 2015-2016 Distinguished Nurse Scholar-in Residence at the Institute of Medicine (IOM) of ... of Biomedical Informatics at Columbia University School of Nursing. A member of the ...
(Date:9/1/2015)... ... September 01, 2015 , ... USA Medical Card, a ... week to coincide with back-to-school and the start of “sick season” for many ... elementary school children are sick an average of 8 to 12 times each ...
(Date:9/1/2015)... Texas (PRWEB) , ... September ... ... LLC, announced today it has established the MAP Recovery Network, the Premier ... addiction treatment providers. This rapidly-growing alliance is dedicated to the provision of ...
Breaking Medicine News(10 mins):Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:Columbia Nursing’s Suzanne Bakken Named Distinguished Institute of Medicine Nurse Scholar-in-Residence 2Health News:USA Medical Card Launches New FAQ Video During Back-to-School 2Health News:MAP Health Management Launches the MAP Recovery Network 2
... 9 The,National Hospice and Palliative Care ... cash grant of $250,000 from a court-approved ... arts, education and,underserved populations., NHPCO will ... and,web-based educational opportunities for hospice professionals, support,research ...
... Heartland is pleased to,announce that their group underwriting ... earned a record dividend of more than $750,000. ... group,s 48 members, which,achieved an outstanding loss ratio ... The Iowa Association of Community Providers (IACP) ...
... more than 600,000 kids taking,part across the country, ... But, no national studies about injury rates in ... to this report from Nationwide Children,s Hospital at:, ... audio, text, graphics and,photos for free and unrestricted ...
... A company founded by an,industry veteran in the ... distribution outlet for the Japanese "Paro" therapy robot through ... announced,today at the RoboBusiness Conference & Expo 2008 in ... Walter Weisel, began its development,through a meeting set up ...
... The Pennsylvania,Academy of Family Physicians Foundation (PAFP/F) is ... student scholarship programs., "The Commonwealth needs more ... care," said PAFP Foundation President Mary Elizabeth,Roth, MD ... the future of family medicine we have to ...
... in Alaska and the Pacific ... Northwest, ... the healthy energy drink mix that has been embraced,by professional athletes, Hollywood ... its product line in,Alaska, Washington and Oregon., "We are very excited ...
Cached Medicine News:Health News:$250,000 Grant Awarded to National Hospice and Palliative Care Organization from Technology Grant Program 2Health News:$250,000 Grant Awarded to National Hospice and Palliative Care Organization from Technology Grant Program 3Health News:$250,000 Grant Awarded to National Hospice and Palliative Care Organization from Technology Grant Program 4Health News:United Heartland Group Program Earns Record Dividend 2Health News:'Paro,' the Baby Seal Service Robot From Japan, Finds a New Home in the United States With Help From JETRO 2Health News:PAFP Golf Tournament to Benefit Student Programs 2Health News:Zipfizz(R) Announces Distribution Deal With the Odom Corporation 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: